NCT01466803View on ClinicalTrials.gov

Effects of Voriconazole on the Pharmacokinetics and Pharmacodynamics of Oral Buprenorphine: A Two-phase Cross-over Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Healthy
Interventions
DRUG

Placebo

The subjects will be given placebo twice a day for 5 days prior to the study

DRUG

Vorikonazole

The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.

Trial Locations (1)

20500

Turku University Hospital, Turku

All Listed Sponsors
lead

Turku University Hospital

OTHER_GOV

NCT01466803 - Effects of Voriconazole on the Pharmacokinetics and Pharmacodynamics of Oral Buprenorphine: A Two-phase Cross-over Study in Healthy Subjects | Biotech Hunter | Biotech Hunter